We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 97.50 | 95.00 | 100.00 | 97.50 | 97.50 | 97.50 | 5,188 | 07:36:53 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -4.46 | 13M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/2/2022 12:02 | The Regional Medical Research Centre is also located in Odisha.ICMR initiated assessment of C-Tb, a new test for detection of latent Tuberculosis in India at ICMR-RMRC Bhubaneswar.This study is being done in collaboration with MOHFW, Govt. of India, WHO & Serum Institute of India, Pvt Ltd. The diagnostic test will facilitate early diagnosis of latent TB cases.".http://www.r | ragnarr | |
10/2/2022 11:50 | Post 9627 🤔 | desflurane | |
10/2/2022 11:35 | Difficult to see how the market could possibly have had any expectations, given how unexpectable the situation is. Which means that the company is really saying their expectations are ahead of their own expectations, which may be unexpected to them, although it should not be, as one can expect expectations to constantly shift. I await the full year figures with an unquantifiable level of expectation. | photon | |
10/2/2022 11:29 | Odisha Ranks Second In Country In TB Eradication: Naba Kisore Das (Odisha is Orissa) Sept 2021https://ommcomne | ragnarr | |
10/2/2022 09:52 | Congratulations are in order. FDBK generated sufficient revenue to pay TO's salary! | ptolemy | |
10/2/2022 09:44 | NCA news is good assuming the target of a contract isn’t just hope. Having run a few businesses I just don’t like being taken for an idiot as an investor with statements about addressable markets, without even seeing it broken down into a realistic plan about how to get a tiny bit of it and what that tiny bit is worth and what timescale is involved. I want to see TO in the Apprentice interviews along with lots of other billion market talking directors. “This isn’t a financial plan - you’re fired !” | yump | |
10/2/2022 09:43 | It works fine, thank you. | ged5 | |
10/2/2022 09:34 | Hope the link works. | lr2 | |
10/2/2022 09:17 | Re #9617 - Wouldn't take much to wind me up Ged. Also, in a senior moment I took your reference to the NCA as National Crime Agency. Thought Bleepa had a police trial I'd missed. | lr2 | |
10/2/2022 09:15 | The government's proposals for health and care integration.Joining up care for people, places and populationsPublished 9 February 2022https://assets.p | ragnarr | |
10/2/2022 09:14 | I guess AIM directors feel the need to put in bullish, sometimes outlandish statements but there was a lot of detail in the statement. The most significant for me was:- "We have significantly expanded the rollout of Bleepa across the NCA with the target of converting this pilot to a revenue generating contract in the relatively near term." Once we get confirmation of that, then yes they will have turned the corner. Good to see you here, Pugugly but please don't wind up LR2. :)) | ged5 | |
10/2/2022 09:12 | Motning PUG - good to see you pop with your usual negativity, hope you are keeping well. | ragnarr | |
10/2/2022 08:47 | yump - Agreed - A bit like a drowning man clutching at straws. Reminds me a bit of the "hope value" utterings of TB | pugugly | |
10/2/2022 08:31 | I think talking about an addressable market of 10bln as the first “highlightR Nevertheless there are revenues from Bleepa. Thats a start. | yump | |
10/2/2022 08:12 | Could they now have turned the corner? Last year results terrible cash burners "Operating loss increased to £1,238k (H1 2021: £918k), reflecting increased investment in product development, commencement of software development amortisation and increased headcount o EBITDA loss increased to £1,033k (H1 2021: £916k) " | pugugly | |
10/2/2022 07:49 | Interim Results for the six months ended 30 November 2021 "Full year outlook expected to be ahead of market expectations" - anyone know what these expectations are? | lr2 | |
09/2/2022 19:35 | Meanwhile the Toronto truckers think their ability to exercise their rights is more important than the majority’s rights, although they like living in a democracy. Disappointing how those people just don’t get the hypocrisy. | yump | |
09/2/2022 19:13 | I think ptolemy may be correct. Given feedbacks record of spending with negligible revenue the institutions that have recently supported them with millions in cash are probably insisting that they can put a magnifying glass over the figures to see exactly where the cash is being spent. If there was a price sensitive deal done then the company would be obliged to inform the market immediately. So I think tomorrow we will see more jam tomorrow with record losses. TO does not have much more time to justify his salary and bonus! | ducatiman | |
09/2/2022 17:23 | Buy Feedback out - consolidate their image tech offering ? | yump | |
09/2/2022 15:31 | Sectra’s radiology module for enterprise imaging, Sectra PACS, has won the prestigious customer satisfaction award Best in KLAS. It has been ranked number one by healthcare providers for the ninth consecutive year in the US, third consecutive year in Canada, and for a first-time in Asia/Oceania. Sounds like a good company to get teamed up with. | lr2 | |
09/2/2022 15:18 | I’ve looked into my crystal ball and I reckon the trial will highlight “extra features requested” as a euphemism for “more development work needed” Several indigestible woolly hats here waiting to be eaten if a post trial contract follows quickly. Probably depends on how many committees are involved in a purchase decision. | yump | |
09/2/2022 15:07 | Meeting could have been requested (ahem, demanded) by institutions drawn into November's placing, now 3 months ago. | ptolemy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions